Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch
Gene Therapies Are Still Hampered By Substantial Delays Between Approval And Launch
Forbes
gene therapy
drug approvals
Biomarin
Bluebird Bio
FDA
Flag link:
Bluebird Bio submits BLA for sickle cell disease gene therapy
Bluebird Bio submits BLA for sickle cell disease gene therapy
Biopharma Reporter
Bluebird Bio
sickle cell disease
lovo-cel
FDA
Flag link:
Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced
Bluebird to miss Q1 deadline for lovo-cel filing, shares sliced
Endpoints
Bluebird Bio
sickle cell disease
gene therapy
FDA
lovo-cel
Flag link:
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
Medicaid, with planned payment pilot, girds for influx of pricey gene therapies
BioPharma Dive
Medicaid
sickle cell disease
gene therapies
Bluebird Bio
Vertex Pharmaceuticals
CRISPR Therapeutics
Flag link:
Bluebird hopes to raise upwards of $100M by selling shares
Bluebird hopes to raise upwards of $100M by selling shares
Endpoints
Bluebird Bio
Flag link:
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
Motley Fool
Moderna Therapeutics
RSV
Bluebird Bio
NASDAQ
Flag link:
FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies
FDA Lifts Partial Clinical Hold On Bluebird Bio's Sickle Cell Disease Studies
NASDAQ
Bluebird Bio
FDA
clinical trials
lovo-cel
sickle cell disease
Flag link:
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Flag link:
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track
Fierce Pharma
Bluebird Bio
ASH 2022
Zynteglo
sickle cell disease
gene therapy
lovo-cel
Flag link:
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Benzinga
Bluebird Bio
priority review vouchers
FDA
Argenx
Flag link:
ASH preview – waiting for Editas
ASH preview – waiting for Editas
EP Vantage
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Flag link:
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
Flag link:
Bluebird wins FDA approval of gene therapy for rare brain disorder
Bluebird wins FDA approval of gene therapy for rare brain disorder
BioPharma Dive
Bluebird Bio
gene therapy
cALD
Skysona
FDA
Flag link:
Go or no go? Bristol’s Tyk2 test
Go or no go? Bristol’s Tyk2 test
EP Vantage
FDA
Bristol Myers Squibb
deucravacitinib
Amylyx Pharmaceuticals
ALS
AMX0035
Ferring Pharmaceuticals
microbiome
RBX2660
Revance Therapeutics
Bluebird Bio
Spectrum Pharmaceuticals
JNJ
Oncopeptides
Flag link:
bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy
bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy
BioSpace
Bluebird Bio
FDA
gene therapy
beta thalassemia
Zynteglo
beti-cel
Flag link:
Go or no go? J&J’s bispecific FDA first
Go or no go? J&J’s bispecific FDA first
EP Vantage
JNJ
Amicus Therapeutics
Acadia Pharma
Bluebird Bio
FDA
Flag link:
FDA Has Ways to Go to Keep Pace with 2020/21 Approvals
FDA Has Ways to Go to Keep Pace with 2020/21 Approvals
BioSpace
FDA
drug approvals
Amicus
Bluebird Bio
Bristol Myers Squibb
Eli Lilly
Marinus Pharma
Amylyx
Novartis
Flag link:
bluebird bio Soars as FDA Adcom Recommends Second Gene Therapy
bluebird bio Soars as FDA Adcom Recommends Second Gene Therapy
BioSpace
Bluebird Bio
FDA
lentiviral vectors
beti-cel
Flag link:
FDA panel backs Bluebird gene therapy despite safety risks
FDA panel backs Bluebird gene therapy despite safety risks
BioPharma Dive
Bluebird Bio
FDA
eli-cel
cALD
Flag link:
Bluebird bio’s future in balance as FDA weighs gene therapy approvals
Bluebird bio’s future in balance as FDA weighs gene therapy approvals
BioPharma Dive
Bluebird Bio
gene therapy
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »